Guideline for PET/CT imaging of neuroendocrine neoplasms with <sup>68</sup>Ga-DOTA-conjugated somatostatin receptor targeting peptides and <sup>18</sup>F-DOPA.
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 28547177.
- Also identified by DOI 10.1007/s00259-017-3728-y.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Neuroendocrine neoplasms are a heterogenous group of tumours, for which nuclear medicine plays an important role in the diagnostic work-up as well as in the targeted therapeutic options. This guideline is aimed to assist nuclear medicine physicians in recommending, performing, reporting and interpreting the results of somatostatin receptor (SSTR) PET/CT imaging using <sup>68</sup>Ga-DOTA-conjugated peptides, as well as <sup>18</sup>F-DOPA imaging for various neuroendocrine neoplasms. The previous procedural guideline by EANM regarding the use PET/CT tumour imaging with <sup>68</sup>Ga-conjugated peptides has been revised and updated with the relevant and recent literature in the field with contribution of distinguished experts.
Medical subject headings
- Dihydroxyphenylalanine
- Gallium Radioisotopes
- Heterocyclic Compounds, 1-Ring
- Neuroendocrine Tumors
- Peptides
- Positron Emission Tomography Computed Tomography
- Receptors, Somatostatin